About bsbh

This author has not yet filled in any details.
So far bsbh has created 192 blog entries.

Better Science, Better Health – IP: Barrier or Creator of Sustainable Healthcare?

4 October, 7.30-8.45 CET, Bad Hofgastein

This breakfast session will offer an open debate on the role of IP in EU healthcare innovation, focused on the appropriate role and balance for both public funding and private investments, supported by new research on EU biotech success factors produced by Vital Transformation. Speakers will discuss in a pro-con format whether IP is a problem or a solution to our healthcare needs, and what role the EU will play in supporting next-generation health technologies to promote a sustainable R&D infrastructure in Europe.

Info & Registration

Better Science, Better Health – IP: Barrier or Creator of Sustainable Healthcare? 2018-07-09T09:25:56+00:00

emif-pictures

EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Pictures An overview 16th March 2016 - Conference Dinner with keynote speech by Sarah Garner Click to view all pictures 17th March 2016 - Full Day Conference at Gerbeaud House Click to view all [...]

emif-pictures 2018-03-06T11:44:49+00:00

emif-speakers

EMIF: E-managing the Future of Health Data 16th-17th March 2016, Budapest Speakers Richard Bergstrom, Director General, EFPIA Miklós Bacskai, Chief Strategy & Business Development Officer, Healthware Alison Bourke, Scientific Director, Real World Evidence, IMS Health Iain Buchan, Clinical Professor Public [...]

emif-speakers 2018-03-06T11:59:57+00:00

emif-about

About EMIF For more information about EMIF, visit the EMIF website Thought Leader Interview: Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF Click here to read the article “When it comes to sharing health data, solving the technical solutions of data sharing is more straightforward [...]

emif-about 2018-03-06T12:02:18+00:00

emif-venue

EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Venues 16th March - Kempinski Hotel Corvinus Budapest Erzsébet tér 7-8, 1051 Budapest If you need a hotel room, please book via the official hotel website. http://www.kempinski.com/en/budapest/hotel-corvinus/welcome/ 17th March - Gerbeaud House 1051 Budapest [...]

emif-venue 2018-03-06T12:01:13+00:00

emif-pres

EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Presentations Click on the names to download specific presentations or scroll to the bottom to get the whole pack. Introduction Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF Discovery: Real World Evidence as a Tool for Translation [...]

emif-pres 2018-03-06T11:54:22+00:00

emif-report

EMIF: E-managing the Future of Health Data 16th-17th March 2015, Budapest Report Whatever the power of digital technologies and no matter the size of the data mountains, the true potential of digitised or machine-readable information relating to health will not be realised without the key ingredient of trust. The IMI-EMIF [...]

emif-report 2018-03-06T11:53:05+00:00

IMI GetReal Closing Meeting – Output

IMI 1 GetReal closing meeting: ‘Delivering tools for real-world evidence development’ 24 November, 2016, Brussels Royal Flemish Academy of Belgium for Science and the Arts Slides Videos Pictures [...]

IMI GetReal Closing Meeting – Output 2018-03-05T18:11:39+00:00

IMI 1 GetReal closing meeting-Speakers

IMI 1 GetReal closing meeting: ‘Delivering tools for real-world evidence development’ 24 November, 2016, Brussels Royal Flemish Academy of Belgium for Science and the Arts Speakers Lucien Abenhaim, MD, PhD & Chairman, LASER Analytica Francesca Cerreta, Senior Scientific Officer, EMA Chris Chinn, Head of [...]

IMI 1 GetReal closing meeting-Speakers 2018-03-05T18:12:38+00:00

Real world big data for clinical research and drug development

30th December, 2017



The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.

Real world big data for clinical research and drug development 2018-04-24T13:18:20+00:00